Adagene Inc.
ADAG
Rank in Stocks
#19812
Adagene Inc. functions as a clinical-stage biopharmaceutical organization,... Adagene Inc. functions as a clinical-stage biopharmaceutical organization, primarily concentrating on the identification, evolution, and fabrication of monoclonal antibody-based therapeutics engineered to combat various types of cancer. The company's developmental pipeline encompasses several investigational assets currently undergoing human trials. Among these is ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibody, which is navigating Phase 1b/2 clinical assessment for individuals with advanced solid tumors and non-Hodgkin's lymphoma. Additionally, Adagene is progressing ADG126, a fully-human anti-CTLA-4 mAb, and ADG116, another human ligand-blocking anti-CTLA-4 mAb, both of which are advancing through Phase 1 studies for the treatment of advanced or metastatic solid tumors. Further along, ADG104, an anti-PD-L1 mAb, is in Phase 2 clinical development, and the innovative anti-CSF-1R mAb, ADG125, is undergoing Phase 1 trials. Beyond its clinical-stage programs, the firm also maintains an active preclinical portfolio. This includes ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is being explored for hematologic and solid tumor indications; ADG138, a novel HER2xCD3 POWERbody designed to target HER2-expressing solid tumors; and ADG152, a CD20xCD3 POWERbody under investigation for its potential to minimize off-tumor toxicities. Adagene Inc. was founded in 2011 and its principal operations are based in Suzhou, China.
Share Price
$2.13
Last synced: 2026-11-11
Market Cap
$96.48M
Change (1 day)
3.90%
Change (1 year)
16.39%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Adagene Inc. (ADAG)
Category
Healthcare
Operating Margin for Adagene Inc. (ADAG)
Operating Margin as of November 2026 TTM: -240.31%
According to Adagene Inc.'s latest financial reports, its current operating margin (TTM) is -240.31%. At the end of 2025 the company had an operating margin of -279.48%.
Operating Margin history for Adagene Inc. from 2018 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -240.31% | -14.02% |
| 2025 | -279.48% | -99.20% |
| 2024 | -34,835.42% | 26,498.01% |
| 2023 | -130.97% | -85.50% |
| 2022 | -903.08% | 26.98% |
| 2021 | -711.18% | -82.19% |
| 2020 | -3,993.68% | 0.00% |
| 2019 | -3,993.68% | 248.16% |
| 2018 | -1,147.09% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| -195.39% | -99.19% |
US
|
|
| 33.87% | -100.14% |
US
|
|
| -116.04% | -99.52% |
US
|
|
| 25.57% | -100.11% |
AU
|
|
| 31.23% | -100.13% |
BE
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Adagene Inc.'s operating margin
What is Adagene Inc.'s operating margin?
Adagene Inc.'s operating margin is -240.31%, as of Nov 2026.
What was Adagene Inc.'s operating margin in 2025?
In 2025, Adagene Inc.'s operating margin was -279.48%, compared with -34,835.42% in 2024.
How has Adagene Inc.'s operating margin changed since 2020?
From 2020 to 2025, Adagene Inc.'s operating margin was highest in 2023 (-130.97%) and lowest in 2024 (-34,835.42%).
How does Adagene Inc.'s operating margin compare with similar companies?
Adagene Inc.'s operating margin (-240.31%) is lower than that of all 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 33.87%.